Characteristics for all enrolled infants and according to whether they had received no or ≥90% in utero exposure to tenofovir.

p-Values from Wilcoxon rank sum tests (continuous) or chi-squared tests (categorical).aExcludes n = 9 with 22%–89% in utero exposure to tenofovir from comparison.bOne regimen with abacavir, one with nevirapine, and 11 with tenofovir.cLopinavir/ritonavir plus lamivudine/tenofovir/nevirapine (one), didanosine/nevirapine (one), didanosine/abacavir (two).dFive switched to second line 9–21 wk into pregnancy (one of whom also had multiple substitutions on first and second line due to hypersensitivity and wrong dispensing); five had first-line substitutions (efavirenz to nevirapine [one] and stavudine to zidovudine [three] plus lamivudine/tenofovir; stavudine to lopinavir/ritonavir [for lipoatrophy]); four had second-line substitutions from efavirenz to nevirapine (two with lamivudine/lopinavir/ritonavir, two didanosine/lopinavir/ritonavir); and two intensified boosted protease inhibitor monotherapy (one with zidovudine/lamivudine/tenofovir for 33 wk, one with nevirapine for 15 wk of the pregnancy).eNevirapine single dose + zidovudine no length given (one), nevirapine only 1 wk (seven), nevirapine 1 wk + zidovudine 1 wk (one), zidovudine only 2–4 wk (four), zidovudine single dose (one), zidovudine and lamivudine 1 wk (three), didanosine 1 wk (one), stavudine 1 week (one).fClosest within 9 wk before (n = 76; median 20 d; IQR 12–30) or after (n = 94; median 25 d; IQR 14–35) delivery for 170/176 pregnancies.g176 pregnancies in 152 mothers: median (IQR) pre-ART CD4 per mother 100 (34–145); p = 0.12 no versus ≥90% tenofovir.NA, not applicable.